AB0585 SINGLE CENTER EXPERIENCE OF CLINICAL PROFILE OF INFLAMMATORY MYOSITIS FROM INDIA

N. Kulkarni1, A. Venugopalan1, M. Saluja1, A. Chopra1 on behalf of
DOCTORS AND RESEARCH SCIENTIST AT CENTER FOR RHEUMATIC DISEASES PUNE. 1Center for Rheumatic Diseases, Rheumatology, Pune, India

Background: Clinical profile of myositis differs in respect of the setting. We present a single center experience from a community based referral center

Objectives: STUDY CLINICAL PROFILE OF INFLAMMATORY MYOSITIS (IM)

Methods: We present data from 114 patients of connective tissue disorders (CTD) with dominant Inflammatory Myopathy (IM) evaluated in CRD where we have patient database since 1996. Standard investigations & ELISA, immunoclot and nephelometry to assay autoantibodies (AAb) were done. Data extraction done from 2005-2017

Results: 36 and 28 patients respectively diagnosed as dominant idiopathic dermatomyositis (DM) and polymyositis (PM); remaining 41 patients showed overlap (OCTD). Mean onset age range 33-40 years in each subset with women dominance. Exclusive proximal muscle involvement seen 64% DM, 67% PM and 43% OCTD. 12 of OCTD showed classical DM rash. Raynaud’s phenomenon was seen in 38% (25% DM, 10% PM, 65% OCTD). 83% OCTD showed inflammatory polyarthritis; DM 29% and PM 42%. Two patients DM also diagnosed malignancy (ovarian CA). 25% DM, nil PM and 31.7% OCTD showed CT based lung findings. Mean creatinine phosphokinase at diagnosis were DM 1580, PM 2239 & OCTD 830. EMG required in 48 patients confirmed diagnosis (DM 17, PM 16 and OCTD 15). Seven patients with diagnostic dilemma poor therapy response required muscle histopathology confirmation. 59% DM, 69% PM and 84% OCTD were seropositive AAb profile positive in 71% (ENA profile available for most). All Patients received steroids. Methotrexate prescribed in (92%) for aggressive disease, IVIG in 2 patients for acute IIM with interstitial pneumonitis. Rituximab was prescribed in 4 resistant cases; all responding favorably. Mortality data of 4 patients(severe myositis(1), interstitial pneumonitis(1), septic shock(1)) was available. Antisynthetase syndrome noted in 9 patients.

Conclusion: Overlap CTD with myositis seems more common profile than DM or PM. Response to therapy was satisfactory with steroids and methotrexate being the mainstay. Rituximab is a promising biological agent in chronic resistant cases.

References:


Acknowledgements: STAFF AND PATIENTS OF CENTER FOR RHEUMATIC DISEASES, PUNE

Disclosure of Interests: none

AB0587 IMMUNOMODULATORY COMBINATION THERAPIES IN PATIENTS WITH DERMATOMYOSITIS / POLYMYOSITIS: A RETROSPECTIVE CROSS-SECTIONAL STUDY

M. T. Qiu1, S. X. Zhang2, J. Cao1, J. Q. Zhang2, J. Qiao1, R. Zhao1, M. J. Chang3, J. Luo1, G. Y. Liu1, C. Gao1, F. X. Li1 1The Second Hospital of Shanxi Medical University, Rheumatology, Taiyuan, China; 2The Second Hospital of Shanxi Medical University, Rheumatology, Taiyuan, China; 3Shanxi Medical University, Taiyuan, China; 4Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Armenia

Background: Dermatomyositis (DM)/Polymyositis(PM) is an autoimmune disease that typically involve the striated muscle with a variable involvement of the skin and other organs. Lymphocyte subsets disorders may contribute to the pathogenesis of DM/PM. It has been discovered that immunomodulatory drugs such as low-dose interleukin-2, rapamycin can help to regulate the lymphocyte subsets and control the disease and improve the prognosis.

Objectives: To investigate the levels of peripheral lymphocyte and CD4+T subsets of DM/PM patients and further to observe the regulatory effect of immunomodulatory therapy on these cells in PM/DM at a relative large-sample size.

Methods: Total 450 patients with DM/PM and 206 healthy controls (HCs) were enrolled in this study. Among these participations, 320 patients received immunomodulatory combination therapies (immunomodulatory drugs include low-dose interleukin-2, rapamycin, metformin, retinoic acid etc). The absolute numbers of T, B, NK, CD4+, CD8+, Th1, Th2, Th17 and Tregs in peripheral blood of these individuals were detected by flow cytometry combined with standard absolute counting beads before and after the treatment.

Results: Patients with DM/PM had lower levels of total T, CD4+, CD8+, Th2, Th17, NK, Th1 and Tregs compared with those of HCs (P < 0.05). After immunomodulatory combination treatments, there was a dramatically increases various lymphocyte subsets such as T, B, CD4+, CD8+, NK, Th1, Th17 and Tregs (P < 0.05). Moreover, the increase in Tregs was much more than that in effector T cells (Teffs), resulting a rebalance of immune systems.

Conclusion: The unbalance of lymphocyte cells should contribute to the pathogenesis of DM/PM patients. Immunomodulatory combination therapies could promote the proliferation and functional recovery of Tregs in patients and might help to alleviate disease activity.

References:


Acknowledgements: None

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.2478

Figure 1. Comparison of peripheral lymphocyte sub-set and CD4+ T subset and CD8+ T subset in patients with DM/PM and healthy controls. The percentage of CD4+ T subset and CD8+ T subset in patients with DM/PM was significantly lower than that in healthy controls. CD4+ T subset and CD8+ T subset in patients with DM/PM were significantly increased. The proportion of CD4+ T subset and CD8+ T subset in patients with DM/PM and healthy controls were significantly different. DM/PM: CD4+ T subset: *P < 0.05, **P < 0.01, ***P < 0.001. CD8+ T subset: *P < 0.05, **P < 0.01, ***P < 0.001.